Why the study?
Are polymorphisms of angiotensin II type 1 and 2 receptors and bradykinin B2 receptor associated with the development of acute myocardial infarction?
Are polymorphisms of angiotensin II type 1 and 2 receptors and bradykinin B2 receptor associated with the development of acute myocardial infarction?
Polymorphisms in angiotensin II type 1 and 2 receptors are associated with the development of acute myocardial infarction, especially in younger patients, suggesting a genetic predisposition.
May indicate genetic AMI predisposition in younger patients; leaves open need for prospective validation before any clinical use.
The renin-angiotensin system is believed to play important roles in the development of acute myocardial infarction, and gene polymorphisms may also be involved. To investigate the genetic background in patients with acute myocardial infarction, we performed a case control study in a Japanese population. The study included 150 patients with acute myocardial infarction and 150 healthy, age- and sex-matched controls. We examined polymorphisms of angiotensin II type 1 receptor (1 166 A / C), type 2 receptor (3123 C / A), and bradykinin B2 receptor (-58 T / C) in these subjects. The allelic frequencies of angiotensin II type I receptor C and angiotensin II type 2 receptor A were significantly higher in the acute myocardial infarction subjects than in the control subjects, and this tendency was more significant in the younger patients. The combined ratios of angiotensin II type 1 receptor C and type 2 receptor A alleles in patients under 64 years old were significantly higher than in their older counterparts. However the total numbers of conventional coronary risk factors (hypertension, hypercholesterolemia, diabetes mellitus, and smoking) in individual subjects were not significantly different between younger and older patients. These polymorphisms were found to be involved in the development of acute myocardial infarction, particularly in the younger patients, and it was concluded that the incidence of acute myocardial infarction might be reduced by management from the genotypes.
No takes yet. Share an insight, caveat, or question.
Aoki et al. (2001) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: